initials_extractor,initials_checker,comment,ma_aut_year,ma_id,ma_e_id,source,chemical_class,chemical_s,chemical_id,health_outcome_type,ICD11_code,health_outcome_class,health_outcome_group,health_outcome_comment,biomarker,model,model_comment,variance_estimate_method,ma_es_measure,,n_ps_e,ma_point_estimate,ma_l_ci,ma_u_ci,ma_se,ma_sd,heterogeneity,heterogeneity (Cochrane Q-statistic),
KM,,NA,ingber_2013,ma_001,ma_m_001,fig2a,OCP,one,DDE,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,,not reported,OR (odds ratio),,15,0.901,0.749,1.084,NA,NA,NA,,
KM,,NA,ingber_2013,ma_001,ma_m_002,fig2b,OCP,one,DDE,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,,not reported,OR (odds ratio),,29,1.107,0.978,1.252,NA,NA,NA,,
KM,,NA,park_2016,ma_002,ma_m_003,fig2,OCP,one,"p,p'-DDE",hypertension,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,,not reported,OR (odds ratio),,6,1.1,1.03,1.18,NA,NA,0,,
KM,,NA,canosancho_2017,ma_003,ma_m_004,fig3,OCP,one,"p,p'-DDE",BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,? (regression coefficient) value,,8,0.13,0.01,0.25,NA,NA,39.5,,
KM,,NA,fu_2020,ma_004,ma_m_005,fig4,OCP,one,"p,p'-DDE",cardiovascular disease,BE2Z,"Diseases of the circulatory system, unspecified",Diseases of the circulatory system,,no,random effects model,,not reported,OR (odds ratio),,11,1.2,1.08,1.34,NA,NA,53.5,,
KM,,NA,fu_2020,ma_004,ma_m_006,fig4,OCP,one,HCB,cardiovascular disease,BE2Z,"Diseases of the circulatory system, unspecified",Diseases of the circulatory system,,no,random effects model,,not reported,OR (odds ratio),,7,1.06,0.89,1.27,NA,NA,45.1,,
KM,,NA,fu_2020,ma_004,ma_m_007,fig4,OCP,one,beta-HCH,cardiovascular disease,BE2Z,"Diseases of the circulatory system, unspecified",Diseases of the circulatory system,,no,random effects model,,not reported,OR (odds ratio),,6,1,0.69,1.46,NA,NA,87.5,,
KM,,NA,hernandezmariano_2020,ma_005,ma_m_008,fig3a,OCP,one,"p,p'-DDE",type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,OR (odds ratio),,8,1.44,1,2.07,NA,NA,44.4,,
KM,,NA,hernandezmariano_2020,ma_005,ma_m_009,fig5,OCP,one,"p,p'-DDE",hypertension,BA00.Z,"Essential hypertension, unspecified",Diseases of the circulatory system,,no,random effects model,,not reported,OR (odds ratio),,4,1.21,1.07,1.38,NA,NA,9.3,,
KM,,NA,tang_2014,ma_006,ma_m_010,fig2c,OCP,one,"p,p'-DDE",type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,22,1.33,1.15,1.54,NA,NA,25,,
KM,,NA,sun_2022,ma_007,ma_m_011,fig2,OCP,multiple,combined ocp,thyroid function,KB62.Y,Other specified transitory neonatal disorders of thyroid function,"Endocrine, nutritional or metabolic diseases",in neonates,no,random effects model,,DerSimonian and Laird,? (regression coefficient) value,,29,0,-0.02,0.02,NA,NA,0,,
KM,,NA,stratakis_2021,ma_008,ma_m_012,fig2a,OCP,one,DDE,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,? (regression coefficient) value,,10,0.12,0.03,0.21,NA,NA,28.15,,
KM,,NA,stratakis_2021,ma_008,ma_m_013,fig2c,OCP,one,HCB,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,? (regression coefficient) value,,5,0.31,0.09,0.53,NA,NA,31.88,,
KM,,NA,luo_2016,ma_009,ma_m_014,fig2,OCP,one,DDT,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,5,1.02,0.81,1.28,NA,NA,0,,
KM,,NA,luo_2016,ma_009,ma_m_015,fig2,OCP,one,DDE,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,11,1.38,1.14,1.66,NA,NA,0,,
KM,,NA,luo_2016,ma_009,ma_m_016,fig2,OCP,one,HCH,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,6,1.42,1.08,1.87,NA,NA,34.4,,
KM,,NA,luo_2016,ma_009,ma_m_017,fig2,OCP,one,Chlordane,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,8,1.93,1.51,2.48,NA,NA,17.7,,
KM,,NA,luo_2016,ma_009,ma_m_018,fig2,OCP,one,HCB,non-Hodgkin lymphoma,2B33.5,"Malignant lymphoma, not elsewhere classified",Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,7,1.54,1.2,1.99,NA,NA,17.7,,
KM,,NA,park_2014,ma_010,ma_m_019,fig2,OCP,one,DDE,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,,not reported,OR (odds ratio),,37,1.03,0.95,1.12,NA,NA,40.9,,
KM,,NA,mosallanejad_2016,ma_011,ma_m_020,fig2,OCP,one,HCB,type 2 diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,not reported,OR (odds ratio),,19,2.23,1.82,2.74,NA,NA,25.95,,
KM,,no overall reported,brown_2006,ma_012,ma_m_021,fig2,OCP,multiple,combined ocp,parkinsons disease,8A00.0,Parkinson disease,Diseases of the nervous system,,no,not reported ,,not reported ,OR (odds ratio),,6,NA,NA,NA,NA,NA,NA,,
KM,,NA,wu_2022,ma_013,ma_m_022,fig3,OCP,one,DDE,preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Conditions originating in the perinatal period,,no,random effects model,,not reported,OR (odds ratio),,5,1.62,0.94,2.82,NA,NA,64.4,,
KM,,NA,yipei_2022,ma_014,ma_m_023,fig2,OCP,one,DDT,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,OR (odds ratio),,17,1.61,1.1,2.36,NA,NA,75,,
KM,,NA,yipei_2022,ma_014,ma_m_024,fig3,OCP,one,DDE,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,no,random effects model,,not reported,OR (odds ratio),,44,1.67,1.41,1.98,NA,NA,73,,
KM,,study does an adjustment for 1ug/g of tissue - we can take these effect sizes also potentially,chittrakul_2021,ma_015,ma_m_025,fig4,OCP,multiple,combined ocp,asthma,CA23.3,Unspecified asthma,Diseases of the respiratory system ,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,2,1.4,1.19,1.64,NA,NA,37.3,,
KM,,NA,lim_2015,ma_016,ma_m_026,fig2,OCP,one,"p,p'-DDE",prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,7,1.41,1.12,1.78,NA,NA,24.8,,
KM,,NA,lim_2015,ma_016,ma_m_027,fig2,OCP,one,trans-Nonachlor,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,5,1.3,0.92,1.82,NA,NA,50.3,,
KM,,NA,lim_2015,ma_016,ma_m_028,fig2,OCP,one,Oxychlordane,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,4,1.18,0.82,1.69,NA,NA,0,,
KM,,this study has a single chemical forest plot with mixed outcomes - then mixed chemical forest plots with single outcomes,bonde_2016,ma_017,ma_m_029,fig3,OCP,one,DDE,"cryptorchidism, hypospadias or testicular cancer",2C82,,Neoplasms,,no,random effects model,,not reported,OR (odds ratio),,13,1.35,1.04,1.74,NA,NA,,,
KM,,NA,mendes_2021,ma_018,ma_m_030,fig2,OCP,one,Oxychlordane,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,DerSimonian and Laird,? (regression coefficient) value,,7,0.04,0,0.07,NA,NA,89.7,,
KM,,NA,mendes_2021,ma_018,ma_m_031,fig3,OCP,one,trans-Nonachlor,BMI,5B81.00,Nutritional disorders,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,DerSimonian and Laird,? (regression coefficient) value,,7,0.02,-0.01,0.06,NA,NA,78.7,,
KM,,NA,mendes_2021,ma_018,ma_m_032,fig4,OCP,one,Oxychlordane,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,DerSimonian and Laird,? (regression coefficient) value,,8,1.96,1.19,3.23,NA,NA,69.8,,
KM,,NA,mendes_2021,ma_018,ma_m_033,fig5,OCP,one,trans-Nonachlor,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,DerSimonian and Laird,? (regression coefficient) value,,10,2.43,1.64,3.62,NA,NA,63.2,,
KM,,NA,mendes_2021,ma_018,ma_m_034,fig6,OCP,one,heptachlor epoxide,diabetes,5A14,"Diabetes mellitus, type unspecified","Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,DerSimonian and Laird,? (regression coefficient) value,,3,1.88,1.42,2.49,NA,NA,0,,
KM,,NA,wang_2021,ma_019,ma_m_035,tab2,OCP,multiple,combined ocp,autismspectrum disorder (ASD),not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",,no,random effects model,,not reported,OR (odds ratio),,2,1.14,0.8,1.65,NA,NA,51.2,2 studies not effect sizes,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_036,fig2,OCP,one,"p,p'-DDE",prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,5,1.02,0.69,1.35,NA,NA,12.7,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_037,fig2,OCP,one,DDT,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,2,0.81,0.35,1.26,NA,NA,0,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_038,fig2,OCP,one,HCB,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,3,0.88,0.18,1.57,NA,NA,36,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_039,fig2,OCP,one,Oxychlordane,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,4,0.91,0.46,1.35,NA,NA,0,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_040,fig2,OCP,one,trans-Nonachlor,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,3,0.88,0.45,1.31,NA,NA,0,,
KM,,CHECK AS THIS IS DIFFERENT TO THE OTHER DDT IN THE STUDY ,lewis-mikhael_2015,ma_020,ma_m_041,fig3,OCP,one,DDT,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,3,1.3,0.94,1.67,NA,NA,13.4,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_042,fig3,OCP,one,heptachlor,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,2,1.34,0.48,2.2,NA,NA,53.5,,
KM,,NA,lewis-mikhael_2015,ma_020,ma_m_043,fig3,OCP,one,gamma-HCH,prostate cancer,2C82,Malignant neoplasms of prostate,Neoplasms,,no,random effects model,,DerSimonian and Laird,OR (odds ratio),,3,1.56,0.82,2.29,NA,NA,41.7,,
KM,,NA,wu_2013,ma_021,ma_m_044,fig2,OCP,one,"p,p'-DDE",diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,not reported,OR (odds ratio),,6,1.25,0.94,1.66,NA,NA,36.8,,
KM,,NA,wu_2013,ma_021,ma_m_045,fig2,OCP,one,"p,p'-DDT",diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,not reported,OR (odds ratio),,3,1,0.54,1.87,NA,NA,0,,
KM,,NA,wu_2013,ma_021,ma_m_046,fig2,OCP,one,HCB,diabetes,5A11,Type 2 diabetes mellitus,"Endocrine, nutritional or metabolic diseases",,no,fixed effects model,,not reported,OR (odds ratio),,4,2,1.13,3.53,NA,NA,21.4,,
KM,,NA,yang_2020,ma_022,ma_m_047,fig3a,OCP,one,beta-HCH,birth weight,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Conditions originating in the perinatal period,,no,fixed effects model,,not reported,? (regression coefficient) value,,7,-22.96,-35.84,-10.07,NA,NA,36.12,,
KM,,NA,liu_2022,ma_023,ma_m_048,fig4a,OCP,multiple,combined ocp,CRP,not reported ,not reported ,Diseases of the musculoskeletal system or connective tissue,,no,,,not reported,? (regression coefficient) value,,9,0.065,0.03,0.099,NA,NA,NA,,
KM,,NA,liu_2022,ma_023,ma_m_049,fig4b,OCP,multiple,combined ocp,IL-1?,not reported ,not reported ,Diseases of the musculoskeletal system or connective tissue,,no,,,not reported,? (regression coefficient) value,,5,0.313,0.05,0.535,NA,NA,NA,,
KM,,NA,liu_2022,ma_023,ma_m_050,fig4c,OCP,multiple,combined ocp,IL-2,not reported ,not reported ,Diseases of the musculoskeletal system or connective tissue,,no,,,not reported,? (regression coefficient) value,,22,0.062,0.004,0.12,NA,NA,NA,,
KM,,NA,liu_2022,ma_023,ma_m_051,fig4d,OCP,multiple,combined ocp,IL-10,not reported ,not reported ,Diseases of the musculoskeletal system or connective tissue,,no,,,not reported,? (regression coefficient) value,,25,0.075,0.019,0.13,NA,NA,NA,,
KM,,NA,canosancho_2019,ma_024,ma_m_052,fig7,OCP,multiple,combined ocp,endometriosis,GA10,Endometriosis,Diseases of the genitourinary system,,no,random effects model,,DerSimonian and Laird,lnRR (risk ratio),,37,0.21,0.12,0.31,NA,NA,50,,
KM,,NA,brauner_2021,ma_025,ma_m_053,fig4a,OCP,multiple,combined ocp,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,maternal exposure,no,random effects model,,not reported,HR (hazard ratio),,11,1.61,0.99,2.61,NA,NA,66,,
KM,,NA,brauner_2021,ma_025,ma_m_054,fig4b,OCP,multiple,combined ocp,testicular cancer,2C80.Z,Malignant neoplasms of male genital organs,Neoplasms,male exposure,no,random effects model,,not reported,HR (hazard ratio),,38,1.24,1.11,1.39,NA,NA,9,,
KM,,NA,adami_1995,ma_026,ma_m_055,,OCP,one,DDE,estrogen related cancer,2C78,"Malignant neoplasms of uterus, part not specified",Neoplasms,,no,not reported ,,not reported ,ratio of means,,34,1.04,0.72,1.45,NA,NA,NA,,
KM,,NA,wang_2016,ma_027,ma_m_056,fig3,OCP,multiple,combined ocp,sperm quality ,not reported,not reported ,Diseases of the genitourinary system,,no,fixed effects model,,not reported,OR (odds ratio),,4,1.98,1.34,2.62,NA,NA,0,,
LR,,NA,liu_2023,ma_028,ma_m_057,fig2,OCP,one,"p,p'-DDT",breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,NA,not reported,OR (odds ratio),,25,1.22,1.03,1.45,NA,NA,77.7,NA,
LR,,NA,liu_2023,ma_028,ma_m_058,fig3,OCP,one,"p,p'-DDE",breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,NA,not reported,OR (odds ratio),,34,1.15,1.01,1.3,NA,NA,59.9,NA,
LR,,NA,liu_2023,ma_028,ma_m_059,fig4,OCP,one,HCB,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,NA,not reported,OR (odds ratio),,14,1.06,0.68,1.65,NA,NA,77.4,NA,
LR,,NA,liu_2023,ma_028,ma_m_060,fig5,OCP,one,HCH,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random effects model,NA,not reported,OR (odds ratio),,22,1.33,1.05,1.67,NA,NA,70.3,NA,
LR,,4 types of OCPs,xu_2023a,ma_029,ma_m_061,fig4,OCP,multiple,combined ocp,sperm count,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,7,1.31,1.19,1.44,NA,NA,96.9,NA,
LR,,5 types of OCPs,xu_2023a,ma_029,ma_m_062,fig4,OCP,multiple,combined ocp,sperm concentration,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,13,1.34,1.1,1.63,NA,NA,95.4,NA,
LR,,6 types of OCPs,xu_2023a,ma_029,ma_m_063,fig4,OCP,multiple,combined ocp,sperm morphology,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,9,1.42,1.02,1.99,NA,NA,97.5,NA,
LR,,3 types of OCPs,xu_2023a,ma_029,ma_m_064,fig4,OCP,multiple,combined ocp,sperm volume,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,5,1.79,1.15,2.79,NA,NA,99.5,NA,
LR,,4 types of OCPs,xu_2023a,ma_029,ma_m_065,fig4,OCP,multiple,combined ocp,sperm motility,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,7,1.87,1.16,3.01,NA,NA,98.2,NA,
LR,,NA,xu_2023a,ma_029,ma_m_066,fig9,OCP,one,DDE,sperm count,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,3,1.01,0.98,1.04,NA,NA,4.3,NA,
LR,,NA,xu_2023a,ma_029,ma_m_067,fig9,OCP,one,DDE,sperm concentration,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,10,1.05,0.98,1.13,NA,NA,49.2,NA,
LR,,NA,xu_2023a,ma_029,ma_m_068,fig9,OCP,one,DDE,sperm morphology,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,6,1,0.97,1.03,NA,NA,0,NA,
LR,,NA,xu_2023a,ma_029,ma_m_069,fig9,OCP,one,DDE,sperm volume,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,2,1,0.99,1.01,NA,NA,0,NA,
LR,,NA,xu_2023a,ma_029,ma_m_070,fig9,OCP,one,DDE,sperm motility,not reported,not reported ,Diseases of the genitourinary system,semen quality,no,random effects model,NA,not reported,OR (odds ratio),,3,1.06,0.77,1.46,NA,NA,77.8,NA,
LR,,postnatal exposure,uldbjerg_2022,ma_030,ma_m_071,fig4B,OCP,multiple,combined ocp,earlier age at menarche,not reported,not reported ,Diseases of the genitourinary system,pubertal timing,no,random effects model,NA,not reported,RR (risk ratio),,5,1.09,0.99,1.19,NA,NA,39,NA,
LR,,girls,lan_2023a,ma_031,ma_m_072,fig2B,OCP,one,DDE,pubertal timing,not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",no,random effects model,NA,not reported,RR (risk ratio),,4,0.89,0.73,1.07,NA,NA,0,NA,
LR,,girls,lan_2023a,ma_031,ma_m_073,fig2B,OCP,one,HCB,pubertal timing,not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",no,random effects model,NA,not reported,RR (risk ratio),,3,0.63,0.49,0.79,NA,NA,0,NA,
LR,,girls,lan_2023a,ma_031,ma_m_074,fig2B,OCP,multiple,combined ocp,pubertal timing,5A91,Endocrine diseases,"Endocrine, nutritional or metabolic diseases","Pubertal timing. From the study: ""Pubertal timing is defined as the time of first appearance of various events during puberty, such as pubic hair growth, breast development, menarche and testicular development.""",no,random effects model,NA,not reported,RR (risk ratio),,4,0.84,0.67,1.06,NA,NA,44.5,NA,
LR,,NA,cartagena_2023,ma_032,ma_m_075,figureS2,OCP,one,DDE,sum of skinfolds,not reported,not reported ,Diseases of the skin,NA,no,not reported ,NA,inverse variance,? (regression coefficient) value,,2,1.09,0.99,1.18,NA,NA,0,NA,
LR,,overall estimates for other chemicals provided but not extracted,sirikul_2023,ma_033,ma_m_076,fig2,OCP,multiple,combined ocp,hypothyroidism,5A00,Hypothyroidism,"Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,inverse variance,OR (odds ratio),,56,1.23,1.14,1.33,NA,NA,43.4,NA,
LR,,table A8.1 is from Supplementary data 2,lin_2023,ma_034,ma_m_077,table A8.1,OCP,one,"p,p'-DDE",risk of preterm birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Conditions originating in the perinatal period,NA,no,random effects model,NA,not reported,? (regression coefficient) value,,3,2.13,0.19,23.35,NA,NA,45.22,NA,
LR,,table A8.2 is from Supplementary data 2,lin_2023,ma_034,ma_m_078,table A8.2,OCP,one,"p,p'-DDE",length of gestational age at birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Conditions originating in the perinatal period,NA,no,random effects model,NA,not reported,? (regression coefficient) value,,8,-0.15,-0.61,0.3,NA,NA,72.17,NA,
LR,,table A8.2 is from Supplementary data 2,lin_2023,ma_034,ma_m_079,table A8.2,OCP,one,HCB,length of gestational age at birth,KA21.4Z,Disorders of newborn related to length of gestation or fetal growth,Conditions originating in the perinatal period,NA,no,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.15,-0.72,0.27,NA,NA,2.94,NA,
LR,,NA,yipei_2023,ma_035,ma_m_080,fig2,OCP,one,DDE,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases",also classified as kidney disease or gout and joint disorders or cardiovascular risk factors,no,random effects model,NA,not reported,OR (odds ratio),,3,3.66,1.77,7.55,NA,NA,80,NA,
LR,,NA,yipei_2023,ma_035,ma_m_081,fig2,OCP,one,DDT,hyperuricemia,5C55.Y,Metabolic disorders,"Endocrine, nutritional or metabolic diseases",also classified as kidney disease or gout and joint disorders or cardiovascular risk factors,no,random effects model,NA,not reported,OR (odds ratio),,3,2.31,1.27,4.2,NA,NA,74,NA,
LR,,NA,cong_2023,ma_036,ma_m_082,fig2,OCP,one,TCDD,breast cancer,2C6Z ,Malignant neoplasms,Neoplasms,"Malignant neoplasms of breast, unspecified",no,random and fixed effects model,NA,not reported,OR (odds ratio),,6,1,0.89,1.12,NA,NA,39.3,NA,
LR,,NA,chen_2023,ma_037,ma_m_083,fig2A,OCP,one,alpha-HCH,protein carbonyls (PC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,0.035,0.017,0.054,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_084,fig2A,OCP,one,beta-HCH,protein carbonyls (PC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,0.204,-0.021,0.429,NA,NA,77,NA,
LR,,NA,chen_2023,ma_037,ma_m_085,fig2A,OCP,one,gamma-HCH,protein carbonyls (PC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,0.111,-0.112,0.335,NA,NA,63,NA,
LR,,NA,chen_2023,ma_037,ma_m_086,fig2A,OCP,one,"p,p'-DDE",protein carbonyls (PC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,0.059,-0.004,0.122,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_087,fig2A,OCP,one,"p,p'-DDT",protein carbonyls (PC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,0.109,-0.166,0.383,NA,NA,73,NA,
LR,,NA,chen_2023,ma_037,ma_m_088,fig2B,OCP,one,alpha-HCH,malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,6,0.02,-0.012,0.041,NA,NA,42,NA,
LR,,NA,chen_2023,ma_037,ma_m_089,fig2B,OCP,one,beta-HCH,malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,6,0.245,-0.011,0.501,NA,NA,95,NA,
LR,,NA,chen_2023,ma_037,ma_m_090,fig2B,OCP,one,gamma-HCH,malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,6,0.185,-0.067,0.437,NA,NA,91,NA,
LR,,NA,chen_2023,ma_037,ma_m_091,fig2B,OCP,one,"o,p'-DDE",malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,0.088,-0.206,0.383,NA,NA,91,NA,
LR,,NA,chen_2023,ma_037,ma_m_092,fig2B,OCP,one,"p,p'-DDE",malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,6,0.121,0.056,0.187,NA,NA,29,NA,
LR,,NA,chen_2023,ma_037,ma_m_093,fig2B,OCP,one,"o,p'-DDT",malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,0.028,-0.008,0.064,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_094,fig2B,OCP,one,"p,p'-DDT",malondialdehyde (MDA),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,0.114,-0.005,0.233,NA,NA,67,NA,
LR,,NA,chen_2023,ma_037,ma_m_095,fig2C,OCP,one,alpha-HCH,total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.068,-0.142,0.005,NA,NA,25,NA,
LR,,NA,chen_2023,ma_037,ma_m_096,fig2C,OCP,one,beta-HCH,total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.195,-0.395,0.006,NA,NA,86,NA,
LR,,NA,chen_2023,ma_037,ma_m_097,fig2C,OCP,one,gamma-HCH,total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.165,-0.314,-0.016,NA,NA,74,NA,
LR,,NA,chen_2023,ma_037,ma_m_098,fig2C,OCP,one,"o,p'-DDE",total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.042,-0.079,-0.004,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_099,fig2C,OCP,one,"p,p'-DDE",total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.129,-0.278,0.019,NA,NA,79,NA,
LR,,NA,chen_2023,ma_037,ma_m_100,fig2C,OCP,one,"o,p'-DDT",total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.146,-0.6,0.308,NA,NA,92,NA,
LR,,NA,chen_2023,ma_037,ma_m_101,fig2C,OCP,one,"p,p'-DDT",total antioxidant capacity (TAC),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,5,-0.111,-0.21,-0.012,NA,NA,57,NA,
LR,,NA,chen_2023,ma_037,ma_m_102,fig2D,OCP,one,alpha-HCH,acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.106,-0.401,0.188,NA,NA,76,NA,
LR,,NA,chen_2023,ma_037,ma_m_103,fig2D,OCP,one,beta-HCH,acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,-0.14,-0.361,0.081,NA,NA,66,NA,
LR,,NA,chen_2023,ma_037,ma_m_104,fig2D,OCP,one,gamma-HCH,acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,4,-0.13,-0.353,0.094,NA,NA,69,NA,
LR,,NA,chen_2023,ma_037,ma_m_105,fig2D,OCP,one,"o,p'-DDE",acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.02,-0.219,0.179,NA,NA,49,NA,
LR,,NA,chen_2023,ma_037,ma_m_106,fig2D,OCP,one,"p,p'-DDE",acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.155,-0.335,0.026,NA,NA,57,NA,
LR,,NA,chen_2023,ma_037,ma_m_107,fig2D,OCP,one,"o,p'-DDT",acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.023,-0.054,0.007,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_108,fig2D,OCP,one,"p,p'-DDT",acetylcholinesterase (AChE),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.085,-0.315,0.144,NA,NA,67,NA,
LR,,NA,chen_2023,ma_037,ma_m_109,fig2E,OCP,one,alpha-HCH,paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.028,-0.061,0.006,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_110,fig2E,OCP,one,beta-HCH,paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.198,-0.53,0.134,NA,NA,90,NA,
LR,,NA,chen_2023,ma_037,ma_m_111,fig2E,OCP,one,gamma-HCH,paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.134,-0.388,0.121,NA,NA,73,NA,
LR,,NA,chen_2023,ma_037,ma_m_112,fig2E,OCP,one,"o,p'-DDE",paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.027,-0.079,0.025,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_113,fig2E,OCP,one,"p,p'-DDE",paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.133,-0.414,0.148,NA,NA,84,NA,
LR,,NA,chen_2023,ma_037,ma_m_114,fig2E,OCP,one,"o,p'-DDT",paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.011,-0.048,0.025,NA,NA,0,NA,
LR,,NA,chen_2023,ma_037,ma_m_115,fig2E,OCP,one,"p,p'-DDT",paraoxonase-1 (PON-1),,oxidative stress,Oxidative stress,NA,yes,random effects model,NA,not reported,? (regression coefficient) value,,3,-0.094,-0.321,0.0133,NA,NA,73,NA,
LR,,NA,maradpour_2021,ma_038,ma_m_116,fig3,OCP,multiple,combined ocp,autismspectrum disorder (ASD),not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,no,fixed effects model,NA,not reported,OR (odds ratio),,14,1.32,1.14,1.53,NA,NA,0,NA,
LR,,NA,maradpour_2021,ma_038,ma_m_117,table 3,OCP,multiple,combined ocp,autismspectrum disorder (ASD),not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,no,fixed effects model,NA,not reported,OR (odds ratio),,14,1.16,0.99,1.36,NA,NA,43.3,NA,unclear as only goves summary estimate
LR,,NA,xu_2023,ma_039,ma_m_118,fig3,OCP,multiple,combined ocp,autismspectrum disorder (ASD),not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,no,random effects model,NA,not reported,OR (odds ratio),,3,1.17,0.86,1.61,NA,NA,24.6,NA,
LR,,NA,xu_2023,ma_039,ma_m_119,fig4,OCP,multiple,combined ocp,attention deficit hyperactivity disorder (ADHD),not reported,Neurodevelopmental disorders,"Mental, behavioural or neurodevelopmental disorders",NA,no,fixed effects model,NA,not reported,OR (odds ratio),,4,1.22,1.03,1.45,NA,NA,0,NA,
KM,,NA,lamat_2022,ma_040,ma_m_120,fig3,OCP,one,HCH,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,6,1.53,1.28,1.78,NA,NA,6.8,NA,
KM,,NA,lamat_2022,ma_040,ma_m_121,fig3,OCP,one,HCB,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,5,1.4,1,1.8,NA,NA,68.4,NA,
KM,,NA,lamat_2022,ma_040,ma_m_122,fig3,OCP,one,DDE,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,7,1.22,1.09,1.34,NA,NA,9,NA,
KM,,NA,lamat_2022,ma_040,ma_m_123,fig3,OCP,one,DDT,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,5,1.28,1.05,1.5,NA,NA,5.8,NA,
KM,,NA,lamat_2022,ma_040,ma_m_124,fig3,OCP,one,Oxychlordane,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,4,1.24,1.01,1.47,NA,NA,0,NA,
KM,,NA,lamat_2022,ma_040,ma_m_125,fig3,OCP,one,trans-Nonachlor,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,5,1.35,1.19,1.52,NA,NA,0,NA,
KM,,NA,lamat_2022,ma_040,ma_m_126,fig3,OCP,one,heptachlor epoxide,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,2,0.99,0.49,1.5,NA,NA,0,NA,
KM,,NA,lamat_2022,ma_040,ma_m_127,fig3,OCP,one,Mirex,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,2,0.73,0.57,0.89,NA,NA,9.9,NA,
KM,,NA,lamat_2022,ma_040,ma_m_128,fig3,OCP,one,Aldrin,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,1,1.23,0.99,1.48,NA,NA,NA,NA,
KM,,NA,lamat_2022,ma_040,ma_m_129,fig3,OCP,multiple,combined ocp,metabolic syndrom,5D2Z,"Metabolic disorders, unspecified","Endocrine, nutritional or metabolic diseases",NA,no,random effects model,NA,not reported,OR (odds ratio),,4,1.28,1,1.56,NA,NA,9.5,NA,
